In JoVE (1)
Other Publications (1)
Articles by Elias Orouji in JoVE
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues Christopher Terranova1, Ming Tang1, Elias Orouji1, Mayinuer Maitituoheti1, Ayush Raman1, Samirkumar Amin2, Zhiyi Liu1, Kunal Rai1 1Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 2The Jackson Laboratory for Genomic Medicine Here, we describe an optimized high-throughput ChIP-sequencing protocol and computational analyses pipeline for the determination of genome-wide chromatin state patterns from frozen tumor tissues and cell lines.
Other articles by Elias Orouji on PubMed
New Role of ID3 in Melanoma Adaptive Drug-resistance Oncotarget. | Pubmed ID: 29299138 Adaptive resistance to targeted therapy such as BRAF inhibitors represents in melanoma a major drawback to this otherwise powerful treatment. Some of the underlying molecular mechanisms have recently been described: hyperactivation of the BRAF-MAPK pathway, of the AKT pathway, of the TGFβ/EGFR/PDGFRB pathway, or the low MITF/AXL ratio. Nevertheless, the phenomenon of early resistance is still not clearly understood. In this report, we show that knockdown of neural crest-associated geneincreases the melanoma sensitivity to vemurafenib short-term treatment. In addition, we observe an-mediated regulation of cell migration and of the expression of resistance-associated genes such asand. In sum, these data suggest ID3 as a new key actor of melanoma adaptive resistance to vemurafenib and as a potential drug target.